STOCK TITAN
  1. Home
  2. Sec-filings
  3. XENE
  4. [Form 4] Xenon Pharmaceuticals Inc. Insider Trading Activity

[Form 4] Xenon Pharmaceuticals Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Xenon Pharmaceuticals (XENE)10/15/2025, the officer received a stock option for 225,000 common shares at an exercise price of $41.9, expiring on 10/14/2035. The option vests 25% on October 15, 2026, with the remaining 75% vesting in equal monthly installments over the next three years.

The filing also reports 30,000 restricted share units (RSUs), vesting 25% on each of the first four anniversaries of the grant date, beginning October 15, 2026. The awards are reported as direct ownership.

Xenon Pharmaceuticals (XENE)) ha presentato un Form 4 che segnala nuove assegnazioni azionarie al suo Chief Financial Officer. Il 15/10/2025, l’ufficiale ha ricevuto una opzione su 225.000 azioni ordinarie ad un prezzo d’esercizio di $41,9, in scadenza il 14/10/2035. L’opzione vince il 25% il 15 ottobre 2026, con il restante 75% che vanno maturando in rate mensili uguali nei prossimi tre anni.

La dichiarazione riporta anche 30.000 RSU (restricted stock units), che maturano 25% ad ognuno dei primi quattro anniversari dalla data di grant, a partire dal 15 ottobre 2026. Le assegnazioni sono riportate come proprietà diretta.

Xenon Pharmaceuticals (XENE)) presentó un Form 4 informando nuevas adjudicaciones de acciones a su Director Financiero. El 15/10/2025, el directivo recibió una opción de compra de 225,000 acciones comunes a un precio de ejercicio de $41.9, con vencimiento el 14/10/2035. La opción vence 25% el 15 de octubre de 2026, y el 75% restante vence en cuotas mensuales iguales durante los próximos tres años.

La declaración también reporta 30,000 RSU (unidades de acciones restringidas), que vesting 25% en cada uno de los primeros cuatro aniversarios desde la fecha de grant, a partir del 15 de octubre de 2026. Las adjudicaciones se reportan como propiedad directa.

Xenon Pharmaceuticals (XENE))에 의해 CFO에게 새로운 주식 보상이 Form 4로 보고되었습니다. 2025년 10월 15일에 해당 임원은 225,000주 보통주의 행사가를 $41.9의 행사 가격으로 받았으며 만료일은 2035년 10월 14일입니다. 이 옵션은 2026년 10월 15일에 25%가 vesting되고, 남은 75%은 향후 3년 동안 매월 균등하게 vest됩니다.

또한 신고서는 30,000 RSU(제한된 주식 단위)를 보고하며, 수여일로부터 처음 4주년 중 매년 25%씩 vesting되며, 시작일은 2026년 10월 15일입니다. 수상은 직접 보유로 보고됩니다.

Xenon Pharmaceuticals (XENE)) a déposé un Form 4 signalant de nouvelles attributions d’actions à son directeur financier. Le 15/10/2025, le cadre a reçu une option d’achat de 225 000 actions ordinaires à un prix d’exercice de $41,9, expirant le 14/10/2035. L’option acquiert 25% le 15 octobre 2026, et les 75% restants sont acquis par versements mensuels égaux sur les trois années suivantes.

Le dépôt mentionne également 30 000 unités d’actions restreintes (RSU), qui seront acquises à hauteur de 25% à chacun des quatre premiers anniversaires à compter de la date d’octroi, à partir du 15 octobre 2026. Les attributions sont déclarées comme propriété directe.

Xenon Pharmaceuticals (XENE)) hat ein Form 4 eingereicht, das neue Eigenkapitalzuteilungen an seinen Chief Financial Officer meldet. Am 15.10.2025 erhielt der Beauftragte eine Aktienoption über 225.000 Stammaktien zu einem Ausübungspreis von $41,9, mit Fälligkeit am 14.10.2035. Die Option vestet 25% am 15. Oktober 2026, der verbleibende 75% vestet in gleichen monatlichen Raten über die nächsten drei Jahre.

Im Bericht wird außerdem 30.000 Restricted Stock Units (RSUs) angegeben, die 25% an jedem der ersten vier Jahrestage ab dem Ausgabedatum vesten, beginnend am 15. Oktober 2026. Die Zuteilungen werden als direkte Eigentum gemeldet.

Xenon Pharmaceuticals (XENE)) تقدمت بتقديم Form 4 يعلنه عن منح أسهم جديدة لمديرها المالي. في 15/10/2025، تلقى المسؤول خيار شراء 225,000 سهماً عاديًا بسعر ممارسة $41.9، وينتهي في 14/10/2035. ي vest الخيار 25% في 15 أكتوبر 2026، في حين vest النسبة المتبقية 75% على أقساط شهرية متساوية خلال السنوات الثلاث التالية.

كما تشير الإفادة أيضًا إلى 30,000 وحدة أسهم مقيدة (RSUs)، التي ستُكتسب 25% في كل واحد من أول أربعة أعوام من تاريخ المنح، ابتداءً من 15 أكتوبر 2026. تعتبر الجوائز مباشرة الملكية.

Xenon Pharmaceuticals (XENE)) 提交了一份 Form 4，报告向其首席财务官发放的新股权奖励。在2025-10-15，该官员获得一个225,000股普通股的股票期权，行使价为$41.9，于2035-10-14到期。该期权在2026-10-15授予时授予25%；其余75%在接下来的三年内按月等额分期归属。

申报还报告了30,000个受限股票单位（RSU），自授予日期起的前四个周年日中的每一个日子授予25%，起始日为2026-10-15。这些奖励被报告为直接所有权。

Positive
  • None.
Negative
  • None.

Xenon Pharmaceuticals (XENE)) ha presentato un Form 4 che segnala nuove assegnazioni azionarie al suo Chief Financial Officer. Il 15/10/2025, l’ufficiale ha ricevuto una opzione su 225.000 azioni ordinarie ad un prezzo d’esercizio di $41,9, in scadenza il 14/10/2035. L’opzione vince il 25% il 15 ottobre 2026, con il restante 75% che vanno maturando in rate mensili uguali nei prossimi tre anni.

La dichiarazione riporta anche 30.000 RSU (restricted stock units), che maturano 25% ad ognuno dei primi quattro anniversari dalla data di grant, a partire dal 15 ottobre 2026. Le assegnazioni sono riportate come proprietà diretta.

Xenon Pharmaceuticals (XENE)) presentó un Form 4 informando nuevas adjudicaciones de acciones a su Director Financiero. El 15/10/2025, el directivo recibió una opción de compra de 225,000 acciones comunes a un precio de ejercicio de $41.9, con vencimiento el 14/10/2035. La opción vence 25% el 15 de octubre de 2026, y el 75% restante vence en cuotas mensuales iguales durante los próximos tres años.

La declaración también reporta 30,000 RSU (unidades de acciones restringidas), que vesting 25% en cada uno de los primeros cuatro aniversarios desde la fecha de grant, a partir del 15 de octubre de 2026. Las adjudicaciones se reportan como propiedad directa.

Xenon Pharmaceuticals (XENE))에 의해 CFO에게 새로운 주식 보상이 Form 4로 보고되었습니다. 2025년 10월 15일에 해당 임원은 225,000주 보통주의 행사가를 $41.9의 행사 가격으로 받았으며 만료일은 2035년 10월 14일입니다. 이 옵션은 2026년 10월 15일에 25%가 vesting되고, 남은 75%은 향후 3년 동안 매월 균등하게 vest됩니다.

또한 신고서는 30,000 RSU(제한된 주식 단위)를 보고하며, 수여일로부터 처음 4주년 중 매년 25%씩 vesting되며, 시작일은 2026년 10월 15일입니다. 수상은 직접 보유로 보고됩니다.

Xenon Pharmaceuticals (XENE)) a déposé un Form 4 signalant de nouvelles attributions d’actions à son directeur financier. Le 15/10/2025, le cadre a reçu une option d’achat de 225 000 actions ordinaires à un prix d’exercice de $41,9, expirant le 14/10/2035. L’option acquiert 25% le 15 octobre 2026, et les 75% restants sont acquis par versements mensuels égaux sur les trois années suivantes.

Le dépôt mentionne également 30 000 unités d’actions restreintes (RSU), qui seront acquises à hauteur de 25% à chacun des quatre premiers anniversaires à compter de la date d’octroi, à partir du 15 octobre 2026. Les attributions sont déclarées comme propriété directe.

Xenon Pharmaceuticals (XENE)) hat ein Form 4 eingereicht, das neue Eigenkapitalzuteilungen an seinen Chief Financial Officer meldet. Am 15.10.2025 erhielt der Beauftragte eine Aktienoption über 225.000 Stammaktien zu einem Ausübungspreis von $41,9, mit Fälligkeit am 14.10.2035. Die Option vestet 25% am 15. Oktober 2026, der verbleibende 75% vestet in gleichen monatlichen Raten über die nächsten drei Jahre.

Im Bericht wird außerdem 30.000 Restricted Stock Units (RSUs) angegeben, die 25% an jedem der ersten vier Jahrestage ab dem Ausgabedatum vesten, beginnend am 15. Oktober 2026. Die Zuteilungen werden als direkte Eigentum gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kelly Thomas Patrick
(Last) (First) (Middle)
3650 GILMORE WAY
(Street)
BURNABY A1 V5G 4W8
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Xenon Pharmaceuticals Inc. [ XENE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option (Right to Buy) $41.9 10/15/2025 A 225,000 (1) 10/14/2035 Common Shares 225,000 $0 225,000 D
Restricted Share Units $0 10/15/2025 A 30,000 (2) (2) Common Shares 30,000 $0 30,000 D
Explanation of Responses:
1. Vesting 25% on October 15, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
2. Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on October 15, 2026.
/s/ Nathaniel Adams, Attorney-in-fact 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did XENE disclose in this Form 4?

Equity grants to the CFO: a stock option for 225,000 shares at $41.9 per share and 30,000 RSUs, both granted on 10/15/2025.

What is the exercise price and expiration for the new option grant?

The option has an exercise price of $41.9 and expires on 10/14/2035.

How do the CFO’s option awards vest?

The option vests 25% on 10/15/2026, with the remaining 75% vesting monthly in equal amounts over the next three years.

What is the RSU vesting schedule?

The 30,000 RSUs vest 25% on each of the first four anniversaries of the grant date, beginning 10/15/2026.

Who is the reporting person and role at XENE?

The reporting person is the company’s Chief Financial Officer, filing as an officer.

Is the reported ownership direct or indirect?

The awards are reported as direct (D) ownership.
Stock XENE logo
Xenon Pharmaceut

NASDAQ:XENE

XENE Rankings

#1700 Ranked by Market Cap
N/A Ranked by Dividends

XENE Latest News

XENE Latest SEC Filings

XENE Stock Data

3.25B
75.53M
0.14%
111.41%
8.96%
Biotechnology
Pharmaceutical Preparations
Link
Canada
BURNABY